Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis  by Alcorta, D.A. et al.
see commentary on page 783
Leukocyte gene expression signatures in
antineutrophil cytoplasmic autoantibody
and lupus glomerulonephritis
DA Alcorta1, DA Barnes2,6, MA Dooley3, P Sullivan1, B Jonas3, Y Liu4, S Lionaki1, CB Reddy1,7, H Chin1,
AA Dempsey2, JC Jennette5 and RJ Falk1
1CB #7155, Division of Nephrology and Hypertension, Department of Medicine, UNC Kidney Center, University Of North Carolina, Chapel
Hill, North Carolina, USA; 2Xceed Molecular, Toronto, Ontario, Canada; 3CB #7005, Division of Rheumatology, Allergy & Immunology,
University of North Carolina, Chapel Hill, North Carolina, USA; 4CB #3260, Department of Statistics and Operations Research, Carolina
Center for Genome Sciences, University of North Carolina, Chapel Hill, North Carolina, USA and 5CB #7525, Department of Pathology
and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
Leukocytes play a major role in the development and
progression of autoimmune diseases. We measured gene
expression differences in leukocytes from patients that were
antineutrophil cytoplasmic autoantibody (ANCA) positive,
patients with systemic lupus erythematosus (SLE) or
rheumatoid arthritis (RA), and healthy donors to explore
potential pathways for clinical intervention. Leukocyte gene
expression profiles were determined on Affymetrix U133A/B
chips in 88 autoimmune patients, 28 healthy donors, and
healthy donor leukocyte cell subtypes that were activated
in vitro. Comparison of gene expression in leukocytes
identified differentially expressed signature genes that
distinguish each donor source. The microarray expression
levels for many signature genes correlated with the clinical
activity of small vessel vasculitis in the ANCA patients;
a result confirmed by quantitative real time-polymerase
chain reaction for 16 relevant genes. Comparison with
in vitro-activated leukocyte subtypes from healthy donors
revealed that the ANCA signature genes were expressed
by neutrophils while the SLE signature genes were
expressed in activated monocytes and T cells. We have
found that leukocyte gene expression data can differentiate
patients with RA, SLE, and ANCA-related small vessel vasculitis.
Monitoring changes in the expression of specific genes may
be a tool to help quantify disease activity during treatment.
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Gene expression profiles have proven to be useful starting
points in the evaluation of a number of diseases, including
cancer and autoimmune diseases. Using DNA arrays to
quantify gene expression levels in the peripheral blood
mononuclear cells (PBMCs), upregulated genes were identi-
fied in adult1,2 and pediatric systemic lupus erythematosus
(SLE) or SLE patients3 which mimic in vitro stimulation of
healthy volunteer peripheral blood mononuclear cells by
viral infection or interferon (IFN) treatment. Additionally,
activity of the ‘IFN signature’ genes parallels the patient’s
clinical disease activity. Although we previously demons-
trated significant upregulation of myeloperoxidase (MPO)
and proteinase-3 mRNAs4 in patients with active vasculitis,
detailed microarray-based expression analysis has not been
performed on the antineutrophil cytoplasmic autoantibody
(ANCA) patient population.
We have performed a systematic analysis of altered gene
expression in leukocytes from healthy volunteers and patients
with three different autoimmune entities: ANCA, rheu-
matoid arthritis (RA), and SLE. We have delibera-
tely compared a pauci-immune glomerulonephritis, ANCA
small vessel vasculitis (ANCA-SVV), with an immune
complex glomerulonephritis, SLE. Leukocytes from RA
patients were analyzed as a prototypic autoimmune control
population. The microarray-based expression analysis iden-
tified three gene signatures representing the ANCA-SVV, SLE,
or healthy volunteer leukocyte populations. Many differen-
tially expressed genes correlated with the level of clinical
activity of the ANCA-SVV patients. These findings were
validated by quantitative real-time polymerase chain reaction
(qRT-PCR) in an expanded ANCA-SVV patient population.
Further, to gain insight into the proximal mediators of
their gene expression pattern, we sought to mimic the
changes detected in vivo in ANCA-SVV and SLE with
in vitro stimulation of leukocyte cell subtypes. Our results
implicate that cell types are believed to be mediators of their
respective diseases: neutrophils and monocytes in ANCA and
T cells in SLE.
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RESULTS
Peripheral blood leukocyte microarray expression profiles
One hundred and fifty-two RNA samples were isolated
from the circulating leukocytes of 116 individuals with SLE,
ANCA, RA, or from healthy control volunteers (Table 1 and
Table S1). Multiple samples were drawn from three ANCA
and 21 SLE patients.
Global gene expression levels were determined on
Affymetrix Hu133A and B gene chips and through pair-wise
comparisons between the groups using all samples in each
group, 1645 genes were shown to be differentially expressed
(see Materials and Methods for criteria). Further statistical
analysis using analysis of variance (ANOVA) identified
541 genes that best differentiated these disease groups.
We have termed this gene set the ANOVA-selected differen-
tially expressed gene set. On the Affymetrix gene chips,
many genes have multiple probe sets representing each gene,
which in some cases represent different splice variants for
that message. The ANOVA-selected differential 541 gene set
represents 459 unique genes. For this gene set and description
of additional gene subsets, we used the larger gene number
representing all genes and possible messages identified, rather
than the number of unique genes, except as noted. Detailed
descriptions of the 1645 and 541 gene sets are available as
Supplementary Material (Tables S2 and S3).
Hierarchical cluster analysis of the ANOVA-selected
differential gene set revealed three major clusters of patient
samples by both visual inspection and by the clustering
algorithm that grouped these samples as distinct branches
(Figure 1, Clusters A, B, and C). Furthermore, three large
clusters of upregulated genes were identified. Using recursive
2-means analysis with the K-means algorithm on the donor
gene expression values, similar patient and gene cluster
distinctions were found by hierarchical clustering (data
no shown). In total, 50 of the 72 SLE samples, and 20 of
the 26 ANCA samples were found within clusters A and B,
respectively, (Figure 1 and Table 2). The majority of the
healthy donor and RA samples separated less distinctly,
but a closer examination of the dendrogram revealed a large
sub-cluster (cluster C) containing 25 of the 28 healthy
volunteers (Figure 1 and Table 2). Based on the distinct
clustering of patient groups, we have termed clusters A, B and
C, SLE, ANCA, and healthy donor clusters, respectively. Each
patient cluster contains a subset of upregulated genes and
represents a unique class signature (Figure 1).
Examination of the gene clusters showed that the ANCA
signature consists of 288 genes representing 256 unique
genes, the SLE signature consists of 205 genes representing
161 unique genes, and the healthy donor signature consists of
48 genes representing 44 unique genes. A concern is gene
selection and clustering may be skewed by differences in the
cell types represented in the disease classes (Table S1).
ANCA-SVV patients have the highest neutrophil counts. It
should be noted that comparison of these genes to those
previously identified as signatures for the various leukocyte
cell types5 revealed 31 neutrophil-specific genes within the
288 ANCA signature (data not shown). Furthermore, the SLE
and RA patients had similar though elevated cell-type
differentials relative to healthy donors and yet have distinct
expression clusters (Figure 1 and Table 2).
The healthy donor signature of ‘upregulated’ genes needs
to be viewed in the context expression levels relative to the
other donor samples. For a given gene, the mean for all
samples is calculated, the expression level in a given sample is
divided by this mean, then this ratio is log transformed.
Hierarchical clustering is calculated from these values.
As the expression level of a gene in healthy volunteers is
the ‘normal’ level, the genes shown as upregulated in this
healthy cluster, therefore, are strongly downregulated in the
ANCA cluster and a subset of the SLE cluster (Figure 1) when
corrected for this bias.
In an attempt to determine possible functional roles of the
genes representing each cluster, these ANCA, SLE, and
healthy donor signature genes were analyzed using the
Expression Analysis Systematic Explorer (EASE) bioinfor-
matic algorithms.6 All three signatures contained over-
represented Gene Ontology gene categories of immunity,
response to pest/pathogen/parasite, and cellular responses for
Table 1 | Demographics of subject populations
Healthy SLE ANCA
RA
Donor groups Array qRT-PCR Array qRT-PCR Array qRT-PCR Array
Unique donors (n) 28 49 40 48 22 69 26
Samples (n) 28 49 72 49 26 97 26
Sex (% male) 61 51 0 4 55 52 27
Racea (% W/AA) 82/4 74/18 43/53 51/43 82/18 81/15 73/27
Ageb (years) 2977 42717 35712 37713 48719 50717 50713
Clinical activityb NA NA BILAG 6.774.9c BILAG 6.375.0d BVAS 10.478.0e BVAS 6.777.4f See noteg
ANCA, antineutrophil cytoplasmic autoantibody; BILAG, British Isles Lupus Assessment Group; BVAS, Birmingham Vasculitis Activity Score; qRT-PCR, quantitative real-time
polymerase chain reaction; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
aW, Caucasian; AA, African American.
bAverage7s.d.; NA, not applicable.
cFrom 72 Samples.
dFrom 38 unique donors.
eFrom 26 samples.
fFrom 93 samples from 65 donors.
gRheumatoid arthritis activity assessment: 1 remission, 1 mild, 7 moderate, 4 moderate-severe, 8 severe, 5 with no score available.
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defense and to external pathogen stimuli, general classes that
might be expected based upon responses of leukocytes. But
each signature contained additional gene categories non-
overlapping with the others groups (Table 3). The ANCA
signature contained 20 genes included in innate immunity,
and genes involved in inflammatory responses, as well as
genes linked to stress and wounding. These genes included
the toll-like receptors 2, 5, and 10, B-cell lymphoma 6, and the
type one interleukin (IL)-1 receptors type I and II (see Table S4
of complete EASE analysis for details). Additionally, IL-18
receptor and IL-18 receptor accessory protein were identified,
and with the IL-1 receptors represent the molecular function
SLE ANCA MixedHealthy
control
Healthy
signature
SLE
signature
ANCA
signature
c
a
b
1
2
Figure 1 | Hierarchical clusters of ANOVA-selected differentially expressed genes in SLE, ANCA, RA, and healthy volunteer leukocyte
samples. The Eisen clustering data are visualized with TreeView and shown as a heat map. Graphical representation of gene expression
differences are shown with green corresponding to down-regulated and red with up-regulated expression with the maximum intensity
corresponding to a change of 0.16 based upon log10. Individual patient samples span the horizontal axis while individual genes are
divided along the vertical axis. SLE, ANCA, and healthy donor gene signatures are labeled. At the top of the figure is the dendrogram
showing the relationship of the donor samples to one another. The white boxes contain genes that enhance differentiation of SLE and
ANCA gene signatures.
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component for IL-1 activity identified. In the SLE signature,
many genes linked to the molecular functions of the antiviral
response included in the helicase and hydrolase categories were
found and include myxovirus-resistance gene 2, IFN-induced
protein 25, 20-50oligoadenylate synthase 1 and 2, and several
additional a- and g-IFN inducible proteins. Similar to the
ANCA gene set, the healthy signature also contains gene linked
to stress and wounding but this is a different and smaller set
including IL-7 receptor, granulysin, perforin 1, and T-cell
receptor alpha (TCR-a). The T-cell receptor complex class
identified consisted of TCR-a listed above and of a trio of cd3Z
antigen, zeta-chain-associated protein kinase and T-cell
receptor-associated transmembrane adaptor 1.
Upon examination of the SLE patients, one may discern
two distinct patient clusters: one without any similarities
with the ANCA gene signature and another patient cluster
showing similar albeit less dramatic upregulation of many
ANCA signature genes. The ANCA and SLE samples can be
distinguished by the large upregulated SLE signature. There
are two smaller groups of genes in the ANCA signature
that provide additional separation from the SLE patient
samples. Group 1 consists of 26 genes and contains multiple
representations of the myristolyated alanine-rich protein
kinase C substrate gene and tumor necrosis factor-induced
protein 6 gene (white box 1, Figure 1). Another most
clearly identified group of upregulated genes identifies ANCA
patients when compared with SLE, RA, or normal control
samples (white box 2, Figure 1). Interestingly, genes found
within this cluster are the B-cell regulator gene, CD24, and
four neutrophil proteins: lipocalin 2, lactotransferrin, and
defensins 1 and 4.
Correlation of expression profile genes with ANCA
disease activity
The fold expression values of the ANOVA-selected differential
gene set relative to healthy control samples were correlated to
their Birmingham Vasculitis Activity Score (BVAS) using
regression analysis. Two hundred and seventy-two of this
gene set showed good correlation based upon a relaxed
statistical cutoff value for correlation of Po0.01 but only 101
genes representing 95 unique genes were identified using a
more robust threshold value of an R40.60 with Po0.004
(Table 4). These 101 genes were termed the ANCA BVAS
genes. Eighty genes were directly correlated with clinical
activity wherein patients with higher BVAS scores show
higher expression of these genes or the converse. The genes
with the highest correlation coefficients of this class were
ring finger protein 24, ubiquitin-conjugating enzyme E2,
and v-ets erythroblastosis virus E26 oncogene homolog 2.
Additionally, 21 genes were indirectly correlated with
clinical activity wherein the patients with higher clinical
activity had lower expression of these genes or the converse.
Adenosine diphosphate-ribosylation factor 7 and the cyto-
skeletal regulatory molecule bridging factor 1 showed the
highest degree of negative correlation. Comparison of this
gene set with neutrophil-specific profiles identified by others5
showed 14 genes in common with the 101 gene BVAS set (see
Table 4, gene annotation (N)). In our SLE cohort, correlation
analysis of expression levels of the 1645 gene set and
British Isles Lupus Assessment Group or SLE Disease Activity
Index clinical activity scores revealed significantly lower
correlation coefficients, with maximum values of RB0.4
(data not shown).
qRT-PCR analysis confirmation of gene expression differ-
ences and association with clinical activity in ANCA patients
Sixteen of the 101 ANCA BVAS genes were selected for
confirmation by qRT-PCR analysis based on their high direct
and indirect correlation coefficients or potential biological
significance. The directly correlated genes selected were ring
finger protein 24, ubiquitin-conjugating enzyme E2, v-ets,
lymphocyte a-kinase, leukotriene B4 receptor (LTB4R), B-cell
lymphoma 6, kelch-like 2, annexin 3, interleukin-1 receptor
type 1 (IL1R1), and arginase-I (ARG-1). The indirectly
correlated genes were adenosine diphosphate-ribosylation
factor-like 7, bridging factor 1, B-cell lymphoma-11B,
Table 2 | Donor sample distribution in patient clusters
Donor sample number in each patient cluster (n)
Patient clusters (Figure 1) Cluster designation Healthy (of 28) ANCA (of 26) SLE (of 72) RA (of 26)
A SLE 0 1 50 4
B ANCA 0 20 9 3
C Healthy control 25 1 3 1
Other clusters Mixed or undesignated 3 4 10 18
ANCA, antineutrophil cytoplasmic autoantibody; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
Table 3 | EASE characterization of 541 differentially expressed gene fragments
Signature No. of gene fragments No. of unique genes GO categories uniquely over-represented
Healthy 48 44 Immunity, stress and wounding, T-cell receptor complex
SLE 205 161 Antiviral, immunity, helicase, hydrolase activity
ANCA 288 256 Innate immunity, inflammation, stress and wounding, IL-1 function
ANCA, antineutrophil cytoplasmic autoantibody; GO, Gene ontology; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
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Table 4 | Spearman correlations of BVAS scores with gene fragments
No. Accession number Gene names
Correlation
coefficient
Correlation
P-value
Direct
1 NM_007219 Ring finger protein 24 0.733 2.69E-06
2 AL562528 Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) 0.729 3.23E-06
3 AL575509 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)a 0.728 3.46E-06
4 AI760166 Lymphocyte alpha-kinase 0.728 3.47E-06
5 U41070 Leukotriene B4 receptor 0.724 4.18E-06
6 NM_001706 B-cell CLL/lymphoma 6 (zinc-finger protein 51)a (N) 0.719 5.23E-06
7 AI538394 Hypothetical protein FLJ14001 (N) 0.714 6.34E-06
8 AW592242 Similar to CG15828-PA (LOC388210), mRNA 0.713 6.72E-06
9 NM_007246 Kelch-like 2, Mayven (Drosophila) 0.708 8.25E-06
10 AW264036 B-cell CLL/lymphoma 6 (zinc-finger protein 51)a (N) 0.706 8.96E-06
11 NM_001995 Acyl-CoA synthetase long-chain family member 1 (N) 0.693 1.58E-05
12 NM_003059 Solute carrier family 22 (organic cation transporter), member 4 (N) 0.691 1.70E-05
13 AK025534 CDNA: FLJ21881 fis, clone HEP02746 0.690 1.74E-05
14 AI768563 Rho GTPase-activating protein 26 0.689 1.82E-05
15 L32185 Solute carrier family 11, member 1 0.686 2.06E-05
16 L13974 Nuclear factor (erythroid-derived 2), 45 kDa (N) 0.684 2.19E-05
17 NM_006931 Solute carrier family 2, member 3 0.679 2.72E-05
18 NM_000717 Carbonic anhydrase IVa 0.677 2.91E-05
19 NM_005384 Nuclear factor, interleukin 3 regulated 0.676 2.95E-05
20 W60806 0.676 2.96E-05
21 NM_004668 Maltase-glucoamylase (alfa-glucosidase) (N) 0.668 4.09E-05
22 AL136944 Solute carrier family 40 (iron-regulated transporter), member 1 0.667 4.24E-05
23 NM_005239 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)a 0.661 5.14E-05
24 BC004564 Dok-like protein 0.660 5.32E-05
25 AL049435 MRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220) 0.660 5.42E-05
26 M63310 Annexin A3 0.659 5.58E-05
27 AL137438 SEC15-like 1 (Saccharomyces cerevisiae) 0.659 5.64E-05
28 NM_024419 Phosphatidylglycerophosphate synthase 0.658 5.68E-05
29 BC004862 Ubiquitin-conjugating enzyme E2R 2 0.658 5.78E-05
30 BE676214 Slingshot homolog 2 (Drosophila) 0.657 6.02E-05
31 NM_024829 Hypothetical protein FLJ22662 0.656 6.06E-05
32 NM_005502 ATP-binding cassette, sub-family A (ABC1), member 1a 0.655 6.28E-05
33 AI420817 Plexin domain containing 2 0.655 6.32E-05
34 BG236273 Transcribed sequences 0.650 7.59E-05
35 NM_000877 Interleukin 1 receptor, type I 0.646 8.78E-05
36 NM_002863 Phosphorylase, glycogen; liver (N) 0.644 9.26E-05
37 AF285167 ATP-binding cassette, sub-family A (ABC1), member 1a 0.643 9.50E-05
38 AK023743 Hypothetical protein FLJ31033 0.643 9.56E-05
39 AK000752 KIAA1181 protein 0.641 1.04E-04
40 N30209 Hypothetical protein MGC34646 0.640 1.05E-04
41 BF433657 Hypothetical protein LOC199675 0.635 1.24E-04
42 NM_002631 Phosphogluconate dehydrogenase (N) 0.634 1.28E-04
43 NM_022718 Matrix metalloproteinase 25 0.633 1.33E-04
44 NM_030666 Serine (or cysteine) proteinase inhibitor, clade B, member 1a 0.631 1.41E-04
45 NM_001315 Mitogen-activated protein kinase 14 0.630 1.45E-04
46 H19232 Hypothetical protein FLJ38964 0.630 1.47E-04
47 NM_003137 SFRS protein kinase 1 0.629 1.53E-04
48 AA702409 Transcribed sequences (N) 0.628 1.53E-04
49 X16354 Carcinoembryonic antigen-related cell adhesion molecule 1 0.628 1.57E-04
50 AI927605 Clone IMAGE:5273245, mRNA 0.628 1.57E-04
51 AK023184 Kinesin family member 1B 0.625 1.70E-04
52 U64094 Interleukin 1 receptor, type II (N) 0.623 1.83E-04
53 AF051151 Toll-like receptor 5 0.621 1.91E-04
54 U66065 Growth factor receptor-bound protein 10 0.621 1.92E-04
55 AL522667 Putative nuclear protein ORF1-FL49 0.621 1.94E-04
56 AL038787 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 0.621 1.95E-04
57 NM_000717 Carbonic anhydrase IVa 0.620 2.00E-04
58 AB046820 KIAA1600 0.617 2.16E-04
59 AI801777 CDNA FLJ31353 fis, clone MESAN2000264 0.617 2.17E-04
60 NM_000045 Arginase, liver 0.617 2.19E-04
61 NM_015364 Lymphocyte antigen 96 0.615 2.32E-04
62 NM_005621 S100 calcium-binding protein A12 (calgranulin C) 0.615 2.33E-04
63 BF593037 0.613 2.43E-04
64 BC006236 Hypothetical protein MGC11324 0.613 2.45E-04
Table 4 is continued on the following page
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lymphocyte-specific tyrosine kinase, killer cell lectin-like
receptor subfamily B member 1, and Perforin 1. In addition,
based upon our previous observations,4 MPO and protei-
nase-3 were included for comparison.
qRT-PCR analysis was performed on an enlarged donor
set of healthy volunteers, ANCA, and SLE patients with
demographics similar to those of patients analyzed on
microarrays (Table 1). Expression differences and clinical
correlations were confirmed for all 18 genes in the expanded
ANCA population (Table 5). Using the fold change values
relative to healthy individuals, the ANCA correlation
coefficients to clinical activity for directly correlated genes
ranged from 0.65 for IL1R1 to 0.37 for MPO. The top five
genes were IL1R1, annexin 3, kelch-like 2, B-cell lymphoma 6,
and ARG-1. Of the genes selected based upon Affymetrixs-
derived data, lymphocyte a-kinase showed the lowest
correlation coefficient at 0.52. For indirectly correlated genes,
coefficients ranged from 0.48 for lymphocyte-specific
protein tyrosine kinase to 0.25 for killer cell lectin-like
receptor subfamily B. Overall, the correlation values in the
q-RT-PCR analysis were not as strong as the array
correlations and the indirectly correlated genes showed
the largest decreases. However, the fold-change values in
the ANCA samples as determined from chip analysis were
confirmed by qRT-PCR analysis (Table 5). The mRNA
levels of the most strongly correlated genes, IL1R1,
annexin 3, kelch-like 2, and B-cell lymphoma 6, showed
3–5-fold increases, while ARG-I gave the largest increase,
B14 fold, relative to healthy donors. Similar fold-change
values were seen between the SLE patient array and
qRT-PCR samples. For the indirectly correlated genes,
qRT-PCR revealed only 1.8–2.4-fold decreases in ANCA
patients, which was similar to changes determined by
chip analysis. Interestingly, only decreases in adenosine
diphosphate-ribosylation factor 7 and Perforin 1 expression
were confirmed for the SLE population.
Table 4 | Continued
No. Accession number Gene names
Correlation
coefficient
Correlation
P-value
65 AL137655 0.613 2.46E-04
66 AL565741 Hypothetical gene supported by AF038182; BC009203 0.612 2.51E-04
67 AI819043 CDNA FLJ32589 fis, clone SPLEN2000443 (N) 0.611 2.62E-04
68 AI963142 CDNA FLJ32274 fis, clone PROST2000036 0.611 2.64E-04
69 AI554300 Serine (or cysteine) proteinase inhibitor, clade B, member 1a 0.610 2.65E-04
70 BF108695 Hypothetical protein LOC285550 0.609 2.73E-04
71 NM_006825 Cytoskeleton-associated protein 4 0.609 2.74E-04
72 NM_012413 Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) (N) 0.609 2.77E-04
73 AF356193 Caspase recruitment domain family, member 6 0.609 2.78E-04
74 AI743596 Tetraspan 2 (N) 0.609 2.78E-04
75 NM_004504 HIV-1 Rev-binding protein 0.605 3.10E-04
76 AF263293 SH3-domain GRB2-like endophilin B1a 0.605 3.12E-04
77 AF257318 SH3-domain GRB2-like endophilin B1a 0.604 3.22E-04
78 AW268357 Ubiquitin-specific protease 32 0.603 3.27E-04
79 AI052659 Transcribed sequences 0.603 3.29E-04
80 AI703476 G protein-coupled receptor 27 0.600 3.57E-04
Indirect
1 BC001051 ADP-ribosylation factor-like 7 0.686 2.05E-05
2 U87558 Bridging integrator 1 0.677 2.92E-05
3 J04132 CD3Z antigen, zeta polypeptide (TiT3 complex) 0.676 2.96E-05
4 AF288571 Lymphoid enhancer-binding factor 1 0.675 3.13E-05
5 NM_022898 B-cell CLL/lymphoma 11B (zinc-finger protein) 0.674 3.19E-05
6 U90548 Butyrophilin, subfamily 3, member A3 0.664 4.61E-05
7 NM_005356 Lymphocyte-specific protein tyrosine kinase 0.663 4.75E-05
8 NM_002258 Killer cell lectin-like receptor subfamily B, member 1 0.663 4.82E-05
9 M12423 T cell receptor alpha locus 0.660 5.28E-05
10 BC005912 Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 0.651 7.36E-05
11 AJ240085 T-cell receptor interacting molecule 0.649 7.86E-05
12 AI967971 Polyribonucleotide nucleotidyltransferase 1 0.642 1.01E-04
13 NM_017933 Hypothetical protein FLJ20701 0.641 1.02E-04
14 X06557 T cell receptor delta locus 0.634 1.29E-04
15 AF043179 0.630 1.47E-04
16 NM_004867 Integral membrane protein 2A 0.621 1.96E-04
17 NM_016523 Killer cell lectin-like receptor subfamily F, member 1 0.614 2.37E-04
18 M85276 Granulysina 0.614 2.37E-04
19 AI817942 Zeta-chain (TCR)-associated protein kinase, 70 kDa 0.612 2.50E-04
20 NM_006433 Granulysina 0.610 2.65E-04
21 AI445650 Perforin 1 (pore-forming protein) 0.608 2.88E-04
BVAS, Birmingham Vasculitis Activity Score.
aDuplicate gene fragments, (N), possible neutrophil-specific genes.
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Expression of ANCA clinical activity genes and SLE signature
genes in individual leukocyte cell types
The expression levels of the ANCA BVAS genes, and the
SLE signature genes were determined in isolated immune
cells stimulated in vitro with a wide range of stimulants
(Table 6 and Figure 2a) and were analyzed by using similar
clustering analysis as was performed on the patient leukocyte
chip samples. From analysis of the ANCA BVAS genes, the
in vitro-stimulated cells segregated into two major sample
clusters and two major gene clusters. The gene clusters
represent the directly and indirectly correlated gene
sets detailed in Table 4. The genes upregulated in the
sample cluster in the left portion of the dendrogram (left
box in Figure 2a and sample tree shown in 2B) contains
the larger directly correlated gene set and represents
expression in unstimulated as well as stimulated neutrophils.
The genes in the lower right portion of the dendrogram
(right box in Figure 2a and sample tree shown in Figure 2c)
are genes correlated inversely with clinical activity and
have the highest expression in both stimulated and
unstimulated CD4þ T cells from healthy donors. Genes
in this group are T-cell receptor (TCR) related, TCR-d,
TCR-a, CD3 z-chain or a part of T-cell signaling, ZAP70,
and LCK, suggesting that there may be a loss of T cells in
our ANCA populations. These results suggest that BVAS
correlated genes are predominantly neutrophil and T-cell
specific genes.
Similar analysis of the SLE gene signature revealed two
large sample clusters (Figure 3a). The long, narrow sample
cluster contains nearly 3/4 of the upregulated genes of this
signature and is found primarily in activated monocytes
stimulated with LPS for 2 and 8 h and CD4þ T lymphocytes
stimulated with either CD3/CD28 or CD3/ICAM1 for 24 and
72 h (Figure 3b). The second cluster to the right of the T-cell
Table 5 | qRT-PCR Taqman confirmation of clinically correlated genes in ANCA patient leukocyte mRNA
qRT-PCR Array
Array list
order
Accession
number Gene name
Spearman
correlation
coefficient
Spearman
correlation,
P-value
Fold
change –
HC vs ANCA
Fold
change –
HC vs SLE
Spearman
correlation
coefficient
Fold
change –
HC vs ANCA
Fold
change –
HC vs SLE
Direct
35 NM_000877 Interleukin 1 receptor,
type 1 (IL1R1)
0.65 o0.0001 5.0 5.2 0.64 3.1 1.6
26 M63310 Annexin A3 0.64 o0.0001 3.7 4.8 0.66 5.0 3.4
9 NM_007246 Kelch-like 2, mayven
(Drosophila)
0.63 o0.0001 3.0 4.5 0.71 2.5 1.6
6 NM_001706 B-cell CLL/lymphoma 6
(zinc-finger protein)
(BCL6)
0.61 o0.0001 4.6 5.3 0.72 2.7 1.7
60 NM_000045 Arginase, type I (ARG-1) 0.59 o0.0001 13.7 9.7 0.62 13.7 3.9
1 NM_007219 Ring finger protein 24 0.59 o0.0001 1.8 2.8 0.73 2.6 2.7
3 AL575509 v-ets erythroblastosis
virus E26 oncogene
homolog 2 (avian)
0.58 o0.0001 1.7 2.9 0.73 2.6 1.7
2 AL562528 Ubiquitin-conjugating
enzyme E2, J1 (UBC6
homolog, yeast)
0.57 o0.0001 1.6 3.5 0.73 2.4 1.7
5 U41070 Leukotriene B4
receptor (LTBR4)
0.56 o0.0001 2.1 2.0 0.72 2.3 1.5
4 AL760166 Lymphocyte alpha-
kinase
0.52 o0.0001 1.7 2.9 0.73 2.3 2.0
NA NM_002777 Proteinase 3 (PR3)a 0.42 o0.0001 18.7 13.4 NA 6.8 1.4
NA J02694 Myeloperoxidase
(MPO)a
0.37 0.0020 8.0 8.3 NA 6.7 2.1
Indirect
7 NM_005356 Lymphocyte-specific
protein tyrosine kinase
0.48 o0.0001 2.2 1.1 0.66 2.5 1.4
1 BC001051 ADP-ribosylation
factor-like 7
0.47 o0.0001 2.1 1.3 0.69 2.5 1.4
2 U87558 Bridging factor 1 0.42 o0.0001 1.8 1.3 0.68 2.7 1.7
5 NM_022898 B-cell CLL/lymphoma
11B (zinc-finger
protein)
0.41 o0.0001 1.9 1.5 0.67 2.7 1.6
21 AI445650 Perforin 1 (pore
forming protein)
0.38 0.0020 2.4 1.8 0.61 2.6 1.8
8 NM_002258 Killer cell lectin-like
receptor subfamily B,
member 1
0.25 0.0120 1.9 1.0 0.66 3.3 2.0
ADP, adenosine diphosphate; ANCA, antineutrophil cytoplasmic autoantibody; NA, not applicable; qRT-PCR, quantitative real time-polymerase chain reaction.
aGene selection based upon previous work.4
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cluster (Figure 3a) contains a more restricted gene subset
(upregulated genes at top and bottom of the dendrogram)
and consists of control and stimulated neutrophil samples.
DISCUSSION
We have performed detailed expression profiling of leuko-
cytes from patients with ANCA-SVV and glomerulonephritis
and compared them to a healthy donor population, patients
with SLE glomerulonephritis as an autoimmune vasculitis
control population and rheumatoid arthritis (RA) as an
autoimmune non-vasculitic population. Our studies have
revealed distinct gene expression profiles in the ANCA and
SLE populations. In addition, many differentially expressed
genes showed strong correlation with the degree of clinical
activity in the ANCA patients, a result confirmed by qRT-
PCR in a subset of genes. Similar to other reports,1–3 our SLE
signature contains the IFN inducible genes (genes induced in
normal leukocytes by IFNs and viral infection) as well many
additional genes. Interestingly, a subset of SLE signature
genes is upregulated in activated normal T cells. These results
lead us to hypothesize that changes in gene expression in the
circulating leukocytes in patients with ANCA are involved in
the clinical manifestations of the disease and targeting these
altered genes may have therapeutic efficacy.
Our studies of in vitro-stimulated leukocytes show that the
genes that correlated with clinical activity in ANCA patients
are neutrophil specific, while the genes in the SLE signature
represent activated T cells. ANCA-SVV patients have elevated
absolute neutrophil counts relative to other cell types. A
comparison of the 411 neutrophil signatures genes identified
by Palmer et.al.5 to ANCA and BVAS gene sets revealed only
B10%, 31 genes, overlap with our original 288 ANCA
signature genes. A similar small percentage (14 of 101) of
overlap was noted with the BVAS gene set. Only one of the 14
BVAS-correlated neutrophil genes (BCL-6) was correlated
with clinical activity within the qRT-PCR-validated gene set.
BCL-6 has been shown to play a key role in B-cell lymphoma
development.7 Further, SLE and RA patient populations both
manifest similar degrees of neutrocytosis but their gene
expression profiles are dramatically different from those of
ANCA patients. These observations suggest that our ANCA
gene signature is not the consequence of a skewed cell type
distribution of leukocyte subtypes. Additional array studies
on specific leukocyte subtypes might help to delineate their
respective contributions to the vasculitic process in ANCA
patients. On a practical and ethical side, such studies would
be difficult to perform because of the large blood volume
samples required for array hybridization studies in these
seriously ill patients.
The study of leukocytes is relevant to the exploration of
ANCA-SVV as the interaction of ANCA with neutrophils and
monocytes have proven that neutrophils are one of the
primary effector cell types causing vascular wall inflamma-
tion and damage. Both in vitro8–10 and in vivo animal studies
support the effector role of the ANCA-neutrophil interaction
in SVV.11,12 Previous in vitro experiments have shown that
addition of either proteinase-3 or MPO-specific ANCA
patient sera to isolated neutrophils leads to cell activation
and degranulation.9,13 The direct pathogenicity of ANCA has
been supported by experimental results in an animal model
for pauci-immune MPO ANCA glomerulonephritis.11,12
Vasculitis and pauci-immune glomerulonephritis can be
induced in mice by either the introduction of anti-MPO
antibodies generated in MPO knockout mice by MPO
immunization into wild-type mice or the transfer of similarly
produced anti-MPO reactive splenocytes into Rag2/
animals. Further, this glomerulonephritis can be blocked by
depletion of circulating neutrophils by use of anti-neutrophil
antibodies.
Our expression analysis using both Affymetrix chips and
qRT-PCR has identified genes with strong correlations with
clinical activity in ANCA patients. Of the genes directly
correlated with BVAS clinical activity, we note four of
particular interest whose proteins may have potential
functional implications in ANCA pathophysiology: annexin
A3, a possible modulator of coagulation, arginase I (ARG-1),
Table 6 | Healthy donor leukocyte cell subtypes: cells and
in vitro stimulants
Cell type Agent (concentration) Exposure time(s)
CD4+T lymphocytes TPAa (100 nM) and
Ionomycin (2 mM)
2 h/8 h
TPA (100 nM) and anti-CD3
IgG (1 mg/ml)
Anti-CD3 IgG (70 ng/ml) and
ICAM (17 ng/ml)
Anti-CD3 IgG (1 mg/ml) and
anti-CD28 IgG (10 mg/ml)
CD19+B- lymphocytes IL4 (100 ng/ml) and LPSb
(1 mg/ml)
3 days/6 days
TPA (100 nM) and Ionomycin
(2 mM)
2 h/8 h
Anti-IgG (100 mg/ml)
LPS (1 mg/ml)
CD14+ monocytes LPS (1 mg/ml) 2 h/8 h
Escherichia coli K12
(five bacteria/cell)
30 min/120 min
Borrelia burgdorferi
(five bacteria/cell)
Neutrophils G-CSF (1 ng/ml) 30 min/120 min
LPS (100 ng/ml)
E. coli K12 (5 bacteria/cell)
B. burgdorferi (5 bacteria/cell)
Yersinia pestis (5 bacteria/cell)
IgD+ cells By isolation from tonsillar tissue
CD38+ cells By isolation from tonsillar tissue
Differentiated cells
Dendritic cells Monocytes with GM-CSF
(200 pg/ml)/IL-4 (400 pg/ml)
7 days
Macrophages Dendritic cells with M-CSF
(1.5 ng/ml)
10 days
G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte macrophage
colony stimulating factor; IgG, immunoglobulin G; IL, interleukin; M-CSF, macro-
phage colony stimulating factor
aTetradecanoylphorbol 13-acetate.
bBacterial lipopolysaccharide.
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a regulator of nitric oxide, and IL1R1 and LTB4R, both of
which are involved in inflammatory signaling via, respec-
tively, ILs and leukotrienes.
Increased annexin A3 expression in leukocyte strongly
mirror increases in clinical activity in ANCA patients. This
change may lead to enhanced neutrophil activation and/or
the promotion of vascular bleeding due to its anti-
coagulation activity.14 Annexins are a family of proteins
characterized by a repeated 70 amino-acid domain which
binds to phospholipids and membranes in a calcium-
dependent manner and may link calcium signaling to
membrane functions such as enhancement of membrane
fusion and recruitment of specific proteins to the mem-
brane.15 These functions may influence cell differentiation
and migration. Additionally, annexin A3 has been shown to
promote neutrophil granule aggregation which potentially
might modulate the degree of neutrophil degranulation.16
Annexin A3 has anti-phospholipase A2 activity which may
modulate cellular signaling.14 Furthermore, annexin A3 has
been implicated as an angiogenic factor based upon its ability
to induce tubule formation and migration of cultured
human umbilical vein endothelial cells possibly through its
ability to enhance transcription of hypoxia-induced factor 1
transcription factor.17 Finally, annexin A3 proteins levels
correlated with growth activity of rat hepatocytes18 and
decreased annexin A3 mRNA levels through the expression of
interference RNA resulted in decreased hepatocyte cell
division.19 Based upon this diverse but potentially synergistic
biochemical signaling, annexin A3 may be a key regulator of
the neutrophil-endothelial cell microenvironment which is at
the leading edge of vasculitic activity.
ARG-1 has been implicated in many models of glomer-
ulonephritis,20 stroke,21 and in other inflammatory pro-
cesses.22 Munder et al.23 showed that high levels of ARG-1 are
found in the azurophilic granules of human granulocytes,
and is locally released at sites of strong inflammation,
resulting in ARG-1 release and arginine depletion, ultimately
leading to the suppression of both T-cell proliferation as well
as cytokine synthesis.24 In addition, inhibition of nitric oxide
synthesis by systemic ARG-1 administration accelerates
nephrotoxic nephritis model in rats.25 Finally, regulation of
ARG-1/nitric oxide synthase pathway can modulate
granuloma formation, a pathological manifestation in one
form of ANCA-SVV, Wegener’s granulomatosis. In an
animal model of schistosomiasis, inactivation of ARG-1 led
to a decrease in the size of schistosome-induced granuloma,26
Monocytes
Neutrophils B cells T cells
4164 Neutrophils Yersinia
4170 Neutrophils G or GM-CSF
48480 CD4+CD3+CD28 2h
48668 CD4+TPA+CD3 2h
48674 CD4+TPA+CD3 2h
48543 CD4+TPA+CD3 2h
52490 CD4+ICAM+CD3 2h
58549 CD4+ICAM+CD3 2h
48550 CD4+ICAM+CD3 8h
48490 CD4+ICAM+CD3 8h
47195 CD4+ICAM+CD3 2h
23274 CD4+control
47193 CD4+control
48548 CD4+control
48539 CD4+control
48479 CD4+control
48482 CD4+control
48476 CD4+control
47071 CD4+control
47056 CD4+control
47391 CD4+control
48667 CD4+control
47196 CD4+control
23279 CD4+control
47190 CD4+control
48446 CD4+control
48530 CD4+control
23284 CD4+control
47199 CD4+control
52488 CD4+CD3+CD28 2h
48553 CD4+CD25+
47076 CD4+CD25+
47396 CD4+CD25+
47395 CD4+CD25+
48554 CD4+CD25+
47075 CD4+CD25+
47189 CD4+TPA+CD3 2h
4169 Neutrophils G or GM-CSF
4168 Neutrophils G or GM-CSF
4167 Neutrophils control
23256 Neutrophils control
38996 Neutrophils control
38738 Neutrophils control
38342 Neutrophils control
42352 Neutrophils control
24660 Neutrophils control
45306 Neutrophils control
19365 Neutrophils control
5085 Neutrophils Yersinia
5083 Neutrophils Yersinia
5086 Neutrophils Yersinia
5084 Neutrophils Yersinia
5087 Neutrophils Yersinia
4166 Neutrophils Yersinia
41803 Neutrophils LPS 120′
39000 Neutrophils LPS 120′
39003 Neutrophils E. coli 120′
48694 Neutrophils E. coli 120′
38343 Neutrophils E. coli 120′
33032 Neutrophils E. coli 120′
45692 Neutrophils E. coli 30′
27115 Neutrophils E. coli 120′
38344 Neutrophils E. coli 30′
45690 Neutrophils Borrelia 30′
37538 Neutrophils LPS 30′
38997 Neutrophils LPS 120′
48695 Neutrophils LPS 30′
37539 Neutrophils LPS 120′
39001 Neutrophils LPS 30′
38998 Neutrophils LPS 30′
39004 Neutrophils LPS 30′
42354 Neutrophils LPS 120′
45304 Neutrophils LPS 120′
46197 Neutrophils LPS 30′
44830 Neutrophils LPS 30′
39006 Neutrophils Borrelia 30′
39005 Neutrophils Borrelia 120′
38346 Neutrophils Borrelia 120′
38347 Neutrophils Borrelia 30′
48696 Neutrophils Borrelia 120′
Figure 2 | Expression analysis of the ANCA BVAS genes in in vitro stimulated healthy donor leukocyte cell subtypes (see Table 6).
(a) Expression levels of these genes (Table 4) were determined in stimulated monocytes, T cells, B cells, neutrophils and Natural Killer cells
from healthy donors. (b and c) Predominant sample clusters of neutrophils and T lymphocytes are boxed and are shown.
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suggesting that elevated levels of ARG-1 could enhance
granuloma formation.
In ANCA disease, the inappropriate activation of neu-
trophils caused by ANCA-antigen interaction on neutrophil
cell surfaces9,10 may be augmented by the simultaneous
elevation in the expression of IL1R1 and LTB4R. Increased
expression of IL1R1 may increase the sensitivity of the cells to
circulating IL-1a and IL-1b cytokines, while increased
expression of LTB4R may amplify the cellular response to
inflammatory leukotrienes. IL1R1 has been shown to be a key
mediator of neutrophil recruitment against Staphylococcus
aureus in a murine cutaneous infection model.27 Similarly,
animal knockout models of LTB4R (known as BLT-1) show a
unique requirement for neutrophil recruitment in inflammatory
arthritis28 and antibody-antigen mediated asthma.29 Further-
more, LTB4R expression levels in monocytes are modulated by
both pro- and anti-inflammatory stimuli.30 The synchronous
upregulation of ARG-1, IL1R1, and LTB4R may alter the
number of neutrophils and monocytes recruited to sites of
inflammation and may amplify the activating effect of ANCA
on neutrophils and monocytes, thus leading to inappropriate
neutrophil degranulation and small vessel injury.
There are several limitations of these studies. Lupus
nephritis, ANCA small vessel vasculitis, and rheumatoid
arthritis are heterogeneous disorders. Patient samples were
obtained at varying stages of disease activity and on varying
dosages and types of immunomodulating drugs. In this
study, it was impossible to stratify for individual immuno-
modulating drugs with respect to type, dosage, or duration of
therapy. Nonetheless, ANCA vasculitis and lupus nephritis
patients were on similar combinations and dosages of
medication with the exception that most lupus patients in
Activated CD14+
monocytes
Activated CD4+
T-lymphocytes
24657 Neutrophils E. coli 30′
24659 Neutrophils E. coli 120′
46197 Neutrophils LPS 30′
44830 Neutrophils LPS 30′
53565 Monocytes LPS 2h
52508 Monocytes LPS 2h
52492 Monocytes LPS 2h
48435 Monocytes LPS 2h
47061 Monocytes LPS 8h
52493 Monocytes LPS 8h
48436 Monocytes LPS 8h
47381 Monocytes LPS 8h
48493 Monocytes LPS 8h
16179 CD4+CD3+CD28 72h
16181 CD4+ICAM+CD3 72h
15713 CD4+ICAM+CD3 72h
16176 CD4+ICAM+CD3 72h
16175 CD4+ICAM+CD3 24h
16180 CD4+ICAM+CD3 24h
15712 CD4+ICAM+CD3 24h
15711 CD4+CD3+CD28 72h
16174 CD4+CD3+CD28 72h
16173 CD4+CD3+CD28 24h
16178 CD4+CD3+CD28 24h
15710 CD4+CD3+CD28 24h
24656 Neutrophils control
Figure 3 | Expression analysis of the SLE signature genes in in vitro stimulated healthy donor leukocyte cell subtypes (see Table 6).
(a) Dendrogram of expression levels of these genes as determined in stimulated monocytes, T cells, B cells, and neutrophils from healthy
donors. The predominant sample cluster of activated monocytes and T lymphocytes is boxed and the cells and stimuli used are shown in b.
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our center are also treated with hydroxychloroquine. The
second limitation of this study pertains to working with
relatively small volumes of peripheral blood from patients
who were most generous in their willingness to provide their
tissue in spite of being seriously ill. Thus, isolation of specific
leukocyte subtypes (e.g. T or B lymphocytes) was not possible
because of the limitation in sample blood volume obtained.
For this reason, we were not able to perform duplicate
measurements on the same patient. These limitations not
withstanding, we have identified leukocyte gene expression
profiles in patients suffering from the active autoimmune
diseases of ANCA-SVV and SLE nephritis, which are distinct
from those of RA patients and healthy volunteers. In the
ANCA-SVV patient populations, we have shown a set of
genes whose expression is correlated with the clinical disease
activity. The role of these genes in initiation/progression/
remission will require additional validation in new and
expanded patient populations. It is likely that the pathologic
response in ANCA-SVV may not be the result of altered
expression of a single gene but rather, multiple genes. This
being the case, a complex multi-gene expression analysis and
modeling will be required for more precise validation. Genes
validated through this process may then be targeted for
therapeutic interventions through modulation of their
mRNA expression or functional activity.
MATERIALS AND METHODS
Sample donors
ANCA, SLE, and RA patients were enrolled at University of North
Carolina (UNC) Chapel Hill clinics. Healthy volunteers were enrolled
from both UNC and Gene Logic facilities using an UNC Institutional
Review Board Committee approved protocol. The demographics of
the entire study population including age, ethnicity, gender, and
clinical activity scores are summarized in Table 1. The clinical activity
was determined in SLE patients using the Systemic Lupus
Erythematosis Disease Activity Index31 and the British Isles Lupus
Assessment Group,32 and in ANCA patients using the BVAS.33 The
clinical status of the RA patients was determined using clinician-based
assessment and activity graded as remission, mild, moderate, or
severe. The majority of all patients were on immunomodulatory
agents. For the most part, these patients were on glucocorticoids or
azathioprine, methotrexate, mycophenolate mofeteil, cyclosporine or
cyclophosphamide, individually or in combinations. There was
relative balance of these agents among patient groups except that
samples from nine of the ANCA, four of the SLE and four of the RA
were from donors untreated at the collection time. The major
exception to this generalization was the predominance of hydroxy-
chloroquine therapy in the lupus population.
Patient leukocyte expression was examined on Affymetrixs
HU133 A and B microarrays and then confirmed using qRT-PCR in
expanded patient populations (Table 1) for genes of interest.
Statistical comparisons of the demographics/clinical activities of the
larger qRT-PCR sample set with the Affymetrix sample set for the
same disease/healthy donor group showed no differences except in
the healthy donor sets in which the donors for qRT-PCR analysis
were statistically older (42 versus 29 years) and the ANCA
population in which the qRT-PCR population has a reduction in
the BVAS activity (6.7 versus 10.4).
Blood sample preparation, sample RNA processing, quality
control, and normalization
Blood samples were processed within 1 h of phlebotomy. White cells
were isolated, RNA purified from the cells, and RNA quality assessed
as previously described.34,35 RNA samples were processed and
hybridized to the microarrays at Gene Logic, Inc. (Gaithersburg,
MD, USA) as prescribed by the manufacturer (Affymetrixs, Santa
Clara, CA, USA). Overall, chip intensities were standardized and
expression levels of individual genes determined using Affymetrixs
MAS 5.0 algorithms.
Experimental in vitro activation of leukocyte cell subtypes
Isolated cells were activated under a variety of conditions and
stimulated for a range of reagents and time periods followed by
RNA isolation and chip analysis (see Table 6). CD4þ T
lymphocytes, CD19þ B lymphocytes, and CD14þ monocytes
were obtained by negative selection using antibody-based magnetic
bead (Miltenyi Biotech, Auburn, CA, USA). IgDþ and CD38þ
cells were isolated from germinal centers of tonsillar tissue and
expression was analyzed. Dendritic cells and macrophages
were generated by in vitro stimulations of isolated monocytes
(Table 6).
Microarray data and statistical analysis
Primary expression data were analyzed using Genesis 2.0 (Gene
Logic, Gaithersburg, MD, USA) using samples with b-actin and
glyceraldehyde-3-phosphate dehydrogenase 50/30 ratios greater
than 0.78 or 0.84. Initially, a separate gene set was identified for
each patient population sample set in which a gene was included
if the average expression intensity value was X50 and if X10% of
the samples of that disease had a ‘present’ call as determined by
the Affymetrixs MAS 5.0 algorithm. The gene sets of each donor
group were merged. Expression levels were compared between
each disease/donor set in a pair-wise fashion, and included
all possible pair-wise combinations. A gene was considered
differentially expressed if the fold-change difference was X1.8-fold
and the statistical P-value was less than 0.01, as determined
by a Welch’s t-test in any pair-wise sample set comparison.
Further analysis of the expression data including regression
analysis, and analysis of variance (ANOVA) was performed using
the AVADIS Prophetic software (Strand Genomics, Bangalore,
Karnataka, India).
For cluster analysis, data were log10 transformed, subjected to
mean centering and normalization, then hierarchically clustered
using average linkage or uncentered correlation (Eisen Cluster
software36) or similar methods in Avadis Prophetic software (Strand
Genomics). Clusters were visualized using the program Treeview.36
Additionally, recursive 2-means analysis was performed using the
K-means algorithm in R. Spearman statistical analysis was used for
correlation.
Over-represented functional gene ontology classes within each
cluster were identified by analysis of the unique genes in each
signature using EASE version 2.0 (http://david.niaid.nih.gov/david/
ease.htm) based upon algorithms and databases previously
described.6 EASE scores, representing one-tail Fisher Exact Prob-
ability test values, Po0.001, were considered significant for
over-representation in Biologic Processes, Cellular Components,
and Molecular Function ontologies. For analysis, redundant
fragments for a given gene were removed before analysis to prevent
statistical biasing.
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qRT-PCR assay
Expression changes for genes identified through analysis of the
microarray data were confirmed by qRT-PCR on complementary
DNA and on an ABI Prism 7900HT sequence detection system using
reagents and protocols as per the manufacturers instructions
(Applied Biosystems, Foster City, CA, USA). Primers for selected
genes were designed using Primer Express 2.1 (Applied Biosystems,
Foster City, CA, USA) and were qualified as previously described.34
The fidelity of amplification was confirmed by sequencing the
amplicon. Relative quantitative levels of samples were determined by
the 2ðDDCtÞ method and fold-change calculated relative to a single
reference control sample. For genes with decreased expression, the
inverse of the 2ðDDCtÞ value was taken and assigned a negative
coefficient to better represent fractional values. Cytochrome c
oxidase COX5b subunit mRNA levels were determined and used to
standardize the input RNA amounts assayed.
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